Serological testing for M-type anti-phospholipase A2 receptor antibodies (antiPLA2R Ab) has abrogated the need for kidney biopsy to diagnose membranous nephropathy in the appropriate clinical setting. We report a case of a 63-year-old hypertensive male who presented with nephrotic syndrome associated with autosomal dominant polycystic kidney disease which was effectively diagnosed with the use of antiPLA2R Ab test. He achieved complete remission upon treatment with Rituximab. Hitherto, all anecdotal case reports of this uncommon association were diagnosed only by kidney biopsy. We highlight the usefulness of PLA2RAb especially in such cases of difficult-to-biopsy kidneys.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11883324 | PMC |
| http://dx.doi.org/10.25259/ijn_413_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bilateral drusenoid deposits with subretinal fluid and cystoid macular edema in a serum anti-phospholipase A2 receptor antibody positive patient: A case report.
Heliyon
February 2025
Department of Ophthalmology, Capital Medical University Electric Teaching Hospital (State Grid Corporation of China Beijing Electric Power Hospital), No. 1, Xili, Taipingqiao, Fengtai District, Beijing, 100073, China.
Introduction: Phospholipase A2 receptor (PLA2R) is a major target antigen in idiopathic membranous nephropathy (IMN). IMN was often reported to have retinal vascular abnormalities secondary to hypercoagculability or hypertension. We describe a case of a serum anti-PLA2R antibody positive patient with bilateral drusenoid deposits and subretinal fluid (SRF) and cystoid macular edema (CME) to stress the necessity of fundus examination in anti-PLA2R antibody positive or IMN patients.
View Article and Find Full Text PDFAnti-Phospholipase A2 Receptor Antibody Testing to the Rescue.
Indian J Nephrol
June 2024
Department of Nephrology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India.
Serological testing for M-type anti-phospholipase A2 receptor antibodies (antiPLA2R Ab) has abrogated the need for kidney biopsy to diagnose membranous nephropathy in the appropriate clinical setting. We report a case of a 63-year-old hypertensive male who presented with nephrotic syndrome associated with autosomal dominant polycystic kidney disease which was effectively diagnosed with the use of antiPLA2R Ab test. He achieved complete remission upon treatment with Rituximab.
View Article and Find Full Text PDFObservation of the efficacy and safety of obinutuzumab in the treatment of refractory idiopathic membranous nephropathy.
Int Urol Nephrol
March 2025
Department Nephrology, Qilu Hospital of Shandong University, No. 107, Wenhua West Road, Lixia District, Jinan City, Shandong Province, China.
Background: This study analyzed the clinical data of 25 patients with refractory idiopathic membranous nephropathy (RIMN) treated with obinutuzumab, aiming to investigate its efficacy and safety.
Methods: A retrospective study was conducted on patients with RIMN who were treated with obinutuzumab, admitted to the Department of Nephrology at Qilu Hospital of Shandong University and the Affiliated Hospital of Jining Medical College from March 2022 to November 2023. The treatment of obinutuzumab was determined based on the individual patient's specific circumstances.
Non-Invasive Diagnostic Strategies for Membranous Nephropathy in the NEPTUNE Study.
Clin J Am Soc Nephrol
February 2025
Division of Nephrology, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA.
Background: Clinical practice guidelines recommend that a kidney biopsy is no longer required to confirm a diagnosis of membranous nephropathy (MN) in patients with nephrotic syndrome and a positive test for anti-phospholipase A2 receptor antibodies (PLA2R-Ab). However, the optimal diagnostic strategy for using the PLA2R-Ab enzyme-linked immunosorbent assay (ELISA), PLA2R-Ab indirect immunofluorescence (IIF) test, and genetic risk score for diagnosing MN, including the tests' optimal thresholds for positivity among incident patients with proteinuria, is still unknown.
Methods: We used serum samples at or before the first clinically indicated kidney biopsy from participants in the Nephrotic Syndrome Study Network (NEPTUNE) to analyze test performance characteristics using different combinations and cut-offs of the PLA2R-Ab ELISA, IIF, and genetic risk score for diagnosing MN.
Obinutuzumab in Rituximab-resistant and recurrent membranous nephropathy: a case-series.
J Nephrol
February 2025
Department of Nephrology, The Alfred Hospital, Melbourne, VIC, Australia.
Background: Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults, with high risk of progression to end-stage kidney disease when untreated. Rituximab is commonly used in its treatment however many patients do not respond. Obinutuzumab is a novel anti-CD20 monoclonal antibody for which there is increasing observational evidence in treatment-resistant membranous nephropathy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!